ArticleBMC neurology2026
Influence of PCSK9 inhibitors on early neurological function, inflammatory factors and blood lipids in patients with acute cerebral infarction: a retrospective cohort study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundProprotein Convertase Subtilisin/Kexin Type 9 inhibitors (PCSK9i) reduce low-density lipoprotein cholesterol (LDL-C), stabilize or even reverse atherosclerotic plaques, and decrease the incidence and recurrence of ischemic stroke. However, their role in the acute phase of ischemic stroke remains unclear. This study aimed to evaluate the effects of PCSK9i on neurological function, the inflammatory response, and lipid profiles in patients with acute ischemic stroke (AIS).
methodA total of 180 patients with acute ischemic stroke who met the inclusion and exclusion criteria were enrolled from Baoding No.1 Central Hospital between January 2024 and July 2025. The patients were divided into an observation group (n = 80, treated with PCSK9i combined with standardized treatment) and a control group (n = 100, treated with standardized treatment).Inflammatory factors [interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP)], low-density lipoprotein cholesterol and National Institutes of Health Stroke Scale (NIHSS) scores were compared between the two groups on day 7 (± 1).This study was approved by the Ethics Committee of Baoding No.1 Central Hospital.
resultsAfter treatment, low-density lipoprotein cholesterol levels decreased in both groups, with the observation group showing a more significant reduction (P < 0.05). The level of interleukin-6 in the observation group decreased, whereas that in the control group slightly increased compared with the level at admission (P < 0.05). The National Institutes of Health Stroke Scale scores at discharge were lower than those at admission in both groups, with the observation group showing greater improvement (P < 0.05).
conclusionPCSK9i can effectively reduce the levels of low-density lipoprotein cholesterol and interleukin-6 in patients with acute cerebral infarction and improve the National Institutes of Health Stroke Scale scores. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.